The Clinical and Hemodynamic Course of Cardiogenic Shocks Hospitalized in Critical Care

Cardiogenic shock is a frequent reason for hospitalization in critical care units, with high mortality (50%). Several French registries have been created to improve knowledge of the prognostic factors of cardiogenic shock. In recent years, temporary mechanical circulatory support has become more important in cardiogenic shock. The monitoring of catecholamines is also performed with a global score: the vaso-inotropic score. The purpose of our study is to consider using these new data and techniques to create a cohort of cardiogenic shock within our critical care unit.

This observational study is based on clinical, biological, and hemodynamic data recorded during the ICU stay of patients for cardiogenic shock.

The primary endpoint is the relationship between the hemodynamic evolution of cardiogenic shock and in-hospital mortality.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Cardiogenic Shock Cardiovascular Diseases Heart Diseases Infarction Ischemia Myocardial Infarction Myocardial Ischemia Necrosis Pathologic Processes Pathological Conditions, Signs and Symptoms Shock Shock, Cardiogenic Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

CHU Amiens Picardie

Amiens, France

Location status: Recruiting

Location contact

Christophe Beyls, MD

CONTACT

[email protected]

0322087866

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients hospitalized in ICU for cardiogenic shock
Patient with cardiogenic shock as defined by the FRENSCHOCK2 study criteria

Exclusion criteria

Patient with cardiogenic shock in the context of septic shock and hemorrhagic shock

Treatment and study plan

Primary outcomes

Percentage of in-hospital mortality after cardiogenic shock

Time frame: 5 years
Vaso-inotropic score after cardiogenic shock

Time frame: 5 years

vasoactive-inotropic score (VIS) Maximal VIS (VISmax) is calculated using the highest doses of vasoactive and inotropic medications administered.

VISmax categories: 0-5, >5-15, >15-30, >30-45, and >45 points.

Study contacts

Contact information is provided by the study sponsor or research team.

Christophe Beyls, MD

CONTACT

[email protected]

03 22 08 78 66

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Universitaire, Amiens

Other

Registry information

Acronym: HEMOCARD

Important dates

Study start: 2023
Primary completion: 2028
Study completion: 2029
First posted: Mar 2, 2023
Registry last updated: Mar 2, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting